Skip to content Skip to footer
Subscribe Now
New Drug Designations - February 2025
INSIGHTS+

New Drug Designations – February 2025

Shots:     PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, and NMPA   The February 2025 report covers designations granted to 53 drugs and 4 medical devices, spanning 16 small molecules, 14 biologics, 18 cell and gene therapies & 4 medical devices among…
March 25, 2025

Read more

ThoughtSpot_Evans James
THOUGHTSPOT

Gynecomastia Surgery: A Strategic Advancement in Men’s Health and Confidence

A Growing Conversation in Men's Health As the conversation around men’s health continues to evolve, surgical procedures once viewed as cosmetic are now being recognized for their clinical value and impact on quality of life. One such procedure is gynecomastia surgery. It is gaining attention among healthcare professionals, patients, and wellness-focused brands alike. …
March 25, 2025

Read more

Viewpoints_Anabela Cardoso_Mark Genovese
VIEWPOINTS

Lilly at ACG 2024: Anabela Cardoso and Mark Genovese in Conversation with PharmaShots

Shots:  Lilly presented results from two long-term studies evaluating sustained efficacy in patients treated with mirikizumab for both moderately to severely active Ulcerative Colitis and Crohn’s Disease at ACG 2024  At three years, more than 80 percent of patients with moderately to severely active ulcerative colitis who were on remission sustained long-term remission and relief  …
March 24, 2025

Read more

INSIGHTS+

Know Your Investor: Perceptive Advisors (March’25 Edition)

Shots:   The March edition highlights Perceptive Advisors, a New York-based investment firm specializing in public and private investments within the healthcare and life sciences sectors In 2024, Perceptive Advisors invested approximately $5.81B in 44 companies through six funding rounds, including private and debt financing For the complete report, reach out to us at connect@pharmashots.com  With…
March 20, 2025

Read more

Viewpoints_Uwe Gudat
VIEWPOINTS

Biocon Biologics at AAO 2024: Uwe Gudat in an Invigorating Discussion with PharmaShots

Shots: At the American Academy of Ophthalmology (AAO 2024), Biocon Biologics announced promising results from the extension study of its proposed biosimilar to aflibercept, MYL-1701P The study demonstrated comparable safety, efficacy, and immunogenicity between patients continuing MYL-1701P and those who switched from aflibercept to MYL-1701P Biocon Biologics' Chief Medical Officer, Uwe Gudat, discusses the groundbreaking…
March 17, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (March 10, 2025 – March 13, 2025)  

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars & Animal Health. Check out our full report below:   Incyte Highlights P-III (TRuE-PN) Clinical Program Data of Opzelura (1.5% Ruxolitinib Cream) for Prurigo Nodularis (PN) at AAD 2025  Read More: Incyte  Johnson & Johnson Highlights P-III Clinical Data of Icotrokinra for Plaque Psoriasis at…
March 13, 2025

Read more

PharmaShots Magazine-March-2025 Edition
MAGAZINE

PharmaShots Magazine-March-2025 Edition

Did you know that 60 percent of pharmaceutical production is outsourced? As drug development costs rise, CDMOs have become safe havens for biopharma companies by offering scalable, cost-effective, and cutting-edge technology solutions for drug development and manufacturing.   In March, PharmaShots Magazine is navigating the evolving Biopharma CDMO frontier by decoding trends, illustrative infographics, thought-provoking articles,…
March 13, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (March 03, 2025 – March 07, 2025) 

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars, Animal Health & DigiHealth. Check out our full report below:    GSK Presents Pooled Analysis from P-III (ANCHOR-1 & 2) Trial of Depemokimab for CRSwNP at AAAAI/WAO Joint Congress 2025  Read More: GSK  Daiichi Sankyo Reports Interim Data of P-III (DESTINY-Gastric04) Study…
March 7, 2025

Read more

Key Biosimilars Events of February 2025
INSIGHTS+

Key Biosimilars Events of February 2025

Shots:        Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency         Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients         A major highlight was the Samsung Bioepis & Teva Partners to Commercialize…
March 4, 2025

Read more

Load more